Endokrinologie. Über ein Jahr nach der Zulassung von Dienogest - Kann wirklich so vielen Endometriosepatientinnen geholfen werden?

The paper reviews the endocrine characteristics and clinical development of dienogest (DNG), focusing on results from a Greifswald phase-II trial (initially reported in 1985) and subsequent efforts toward phase-III dose-finding studies that were not fully completed before publication, leaving some criteria (notably endoscopic proof of effect and fertility data) not re-tested in the final approval studies. Across first investigations totaling 223 patients, the authors report consistent symptom improvement in the 75–85% range and an endoscopic remission rate of 87% (with later biopsies interpreting apparent residual lesions as hemosiderin deposits or scars), along with early post-treatment restoration of menstruation and high ovulation rates. The paper also describes a post-therapy pregnancy rate of 55% within a mean of 8 months among previously sterile women, and reports no significant changes in a range of paraclinical and metabolic parameters. This paper is centrally about endometriosis — it discusses dienogest’s hormonal/endometrial effects and clinical outcomes for endometriosis treatment and approval.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works